These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35402023)

  • 1. Stereotactic radiotherapy for lung oligometastases.
    Falcinelli L; Menichelli C; Casamassima F; Aristei C; Borghesi S; Ingrosso G; Draghini L; Tagliagambe A; Badellino S; di Monale E Bastia MB
    Rep Pract Oncol Radiother; 2022; 27(1):23-31. PubMed ID: 35402023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic radiotherapy for oligometastases in the lymph nodes.
    Pasqualetti F; Trippa F; Aristei C; Borghesi S; Colosimo C; Cantarella M; Mazzola R; Ingrosso G
    Rep Pract Oncol Radiother; 2022; 27(1):46-51. PubMed ID: 35402021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic radiotherapy for liver oligometastases.
    Menichelli C; Casamassima F; Aristei C; Ingrosso G; Borghesi S; Arcidiacono F; Lancellotta V; Franzese C; Arcangeli S
    Rep Pract Oncol Radiother; 2022; 27(1):32-39. PubMed ID: 35402041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic radiotherapy for adrenal oligometastases.
    Borghesi S; Casamassima F; Aristei C; Grandinetti A; Di Franco R
    Rep Pract Oncol Radiother; 2022; 27(1):52-56. PubMed ID: 35402020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic radiotherapy for bone oligometastases.
    Colosimo C; Pasqualetti F; Aristei C; Borghesi S; Forte L; Mignogna M; Badii D; Bosio M; Paiar F; Nanni S; Bertocci S; Lastrucci L; Parisi S; Ingrosso G
    Rep Pract Oncol Radiother; 2022; 27(1):40-45. PubMed ID: 35402030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Single-fraction and Multi-fraction Stereotactic Radiotherapy for Patients with 18F-fluorodeoxyglucose Positron Emission Tomography-staged Pulmonary Oligometastases.
    Siva S; Kirby K; Caine H; Pham D; Kron T; Te Marvelde L; Whalley D; Stevens MJ; Foroudi F; MacManus M; Ball D; Eade T
    Clin Oncol (R Coll Radiol); 2015 Jun; 27(6):353-61. PubMed ID: 25698068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic radiotherapy for brain oligometastases.
    Lupattelli M; Tini P; Nardone V; Aristei C; Borghesi S; Maranzano E; Anselmo P; Ingrosso G; Deantonio L; di Monale E Bastia MB
    Rep Pract Oncol Radiother; 2022; 27(1):15-22. PubMed ID: 35402029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic Radiotherapy for Oligometastases in Lymph Nodes-A Review.
    Matsushita H; Jingu K; Umezawa R; Yamamoto T; Ishikawa Y; Takahashi N; Katagiri Y; Kadoya N
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818803597. PubMed ID: 30352542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning.
    Coon D; Gokhale AS; Burton SA; Heron DE; Ozhasoglu C; Christie N
    Clin Lung Cancer; 2008 Jul; 9(4):217-21. PubMed ID: 18650169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study.
    van Der Wel A; Nijsten S; Hochstenbag M; Lamers R; Boersma L; Wanders R; Lutgens L; Zimny M; Bentzen SM; Wouters B; Lambin P; De Ruysscher D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):649-55. PubMed ID: 15708242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
    Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
    Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.
    Grills IS; Yan D; Martinez AA; Vicini FA; Wong JW; Kestin LL
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):875-90. PubMed ID: 14529795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory-gated (4D) FDG-PET detects tumour and normal lung response after stereotactic radiotherapy for pulmonary metastases.
    Siva S; Callahan JW; Kron T; Chesson B; Barnett SA; Macmanus MP; Hicks RJ; Ball DL
    Acta Oncol; 2015; 54(8):1105-12. PubMed ID: 25833329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy.
    Hardcastle N; Hofman MS; Lee CY; Callahan J; Selbie L; Foroudi F; Shaw M; Chander S; Lim A; Chesson B; Murphy DG; Kron T; Siva S
    Radiat Oncol; 2019 Sep; 14(1):164. PubMed ID: 31488175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
    Niibe Y; Nishimura T; Inoue T; Karasawa K; Shioyama Y; Jingu K; Shirato H
    BMC Cancer; 2016 Aug; 16(1):659. PubMed ID: 27542716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.
    Facey K; Bradbury I; Laking G; Payne E
    Health Technol Assess; 2007 Oct; 11(44):iii-iv, xi-267. PubMed ID: 17999839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes.
    Wang HH; Zaorsky NG; Meng MB; Zeng XL; Deng L; Song YC; Zhuang HQ; Li FT; Zhao LJ; Yuan ZY; Wang P; Hao XS
    Oncotarget; 2016 Apr; 7(14):18135-45. PubMed ID: 26919113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
    Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
    Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.